AnaptysBio, Inc.
ANAB
$20.25
-$0.115-0.57%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 17.21% | 10.49% | 48.39% | 11.95% | -17.10% |
Total Depreciation and Amortization | 1.01% | 0.17% | -0.50% | 0.68% | 1.36% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 70.09% | 89.64% | 134.86% | 127.54% | 51.10% |
Change in Net Operating Assets | -437.76% | 133.22% | -2,488.45% | 112.54% | 168.65% |
Cash from Operations | -88.74% | 71.28% | -94.10% | 72.34% | 16.08% |
Capital Expenditure | -18.18% | -29.63% | 6.07% | 78.40% | 82.63% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 1,612.74% | -78.32% | -158.90% | 90.46% | 88.11% |
Cash from Investing | 1,590.70% | -78.36% | -159.77% | 91.35% | 88.06% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 45.35% | -64.24% | 110.23% | 61,460.63% | 25.03% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -102.01% | -69.32% | 606.51% | -743.66% | 2,371.57% |
Cash from Financing | -220.55% | -109.71% | 634.35% | 2,418.68% | 410.48% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -399.78% | -237.86% | -808.39% | 1,443.96% | 130.54% |